- Home
- DTF vs STTK Comparison
DTF vs STTK Comparison
Compare DTF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- STTK
- Stock Information
- Founded
- DTF 1991
- STTK 2016
- Country
- DTF United States
- STTK United States
- Employees
- DTF N/A
- STTK N/A
- Industry
- DTF Investment Managers
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- STTK Health Care
- Exchange
- DTF Nasdaq
- STTK Nasdaq
- Market Cap
- DTF 79.8M
- STTK 83.8M
- IPO Year
- DTF N/A
- STTK 2020
- Fundamental
- Price
- DTF $11.38
- STTK $2.14
- Analyst Decision
- DTF
- STTK Hold
- Analyst Count
- DTF 0
- STTK 6
- Target Price
- DTF N/A
- STTK $2.67
- AVG Volume (30 Days)
- DTF 21.1K
- STTK 1.5M
- Earning Date
- DTF 01-01-0001
- STTK 11-13-2025
- Dividend Yield
- DTF 3.64%
- STTK N/A
- EPS Growth
- DTF N/A
- STTK N/A
- EPS
- DTF 0.44
- STTK N/A
- Revenue
- DTF N/A
- STTK $2,997,000.00
- Revenue This Year
- DTF N/A
- STTK N/A
- Revenue Next Year
- DTF N/A
- STTK N/A
- P/E Ratio
- DTF $24.34
- STTK N/A
- Revenue Growth
- DTF N/A
- STTK N/A
- 52 Week Low
- DTF $10.29
- STTK $0.69
- 52 Week High
- DTF $11.19
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- DTF 61.47
- STTK 58.93
- Support Level
- DTF $11.32
- STTK N/A
- Resistance Level
- DTF $11.42
- STTK $2.01
- Average True Range (ATR)
- DTF 0.07
- STTK 0.21
- MACD
- DTF 0.00
- STTK 0.01
- Stochastic Oscillator
- DTF 80.95
- STTK 99.53
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.